Prostate cancer-Associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4

Nature Medicine

Volumn 23, Issue 9, 2017, Pages 1063-1071

  Dai, Xiangpeng ^a   Gan, Wenjian ^a   Li, Xiaoning ^a,b   Wang, Shangqian ^c   Zhang, Wei ^d,e   Huang, Ling ^a   Liu, Shengwu ^a   Zhong, Qing ^f   Guo, Jianping ^a   Zhang, Jinfang ^a   Chen, Ting ^a   Shimizu, Kouhei ^a   Beca, Francisco ^a   Blattner, Mirjam ^g   Vasudevan, Divya ^g   Buckley, Dennis L ^a   Qi, Jun ^a   Buser, Lorenz ^f   Liu, Pengda ^a,i   Inuzuka, Hiroyuki ^a   Beck, Andrew H ^a   Wang, Liewei ^h   Wild, Peter J ^f   Garraway, Levi A ^a   Rubin, Mark A ^g   Barbieri, Christopher E ^g   Wong, Kwok Kin ^a   Muthuswamy, Senthil K ^a   Huang, Jiaoti ^d   Chen, Yu ^c   Bradner, James E ^a   Wei, Wenyi ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b JILIN UNIVERSITY   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BEIJING HOSPITAL   (China)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h MAYO GRADUATE SCHOOL   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BRD2 PROTEIN; BRD3 PROTEIN; BRD4 PROTEIN; CULLIN; PROTEIN; SPECKLE TYPE POZ PROTEIN; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRD2 PROTEIN, HUMAN; BRD3 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; BRDT PROTEIN, HUMAN; CUL3 PROTEIN, HUMAN; DBET1 COMPOUND; MOLIBRESIB; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; RNA BINDING PROTEIN; SPOP PROTEIN, HUMAN; THALIDOMIDE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; ECTOPIC EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN STABILITY; SOMATIC MUTATION; UBIQUITINATION; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; DRUG RESISTANCE; GENETICS; HEK293 CELL LINE; HELA CELL LINE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PROSTATIC NEOPLASMS;

APOPTOSIS; AZEPINES; BENZODIAZEPINES; CELL PROLIFERATION; CULLIN PROTEINS; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HELA CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS; RNA-BINDING PROTEINS; THALIDOMIDE; TRANSCRIPTION FACTORS; TRIAZOLES; UBIQUITINATION;

EID: 85029059604     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4378     Document Type: Article

References (41)

1. Zeng, L. & Zhou, M.M. Bromodomain: An acetyl-lysine binding domain. FEBS Lett. 513, 124-128 (2002).
2. Wu, S.Y. & Chiang, C.M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282, 13141-13145 (2007).
3. Filippakopoulos, P. & Knapp, S. The bromodomain interaction module. FEBS Lett. 586, 2692-2704 (2012).
4. Filippakopoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13, 337-356 (2014).
5. Belkina, A.C. & Denis, G.V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 12, 465-477 (2012).
6. Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
7. Mertz, J.A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108, 16669-16674 (2011).
8. Asangani, I.A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014).
9. French, C.A. et al. BRD4-NUT fusion oncogene: A novel mechanism in aggressive carcinoma. Cancer Res. 63, 304-307 (2003).
10. Crawford, N.P. et al. Bromodomain 4 activation predicts breast cancer survival. Proc. Natl. Acad. Sci. USA 105, 6380-6385 (2008).
11. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
12. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010).
13. Fong, C.Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538-542 (2015).
14. Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543-547 (2015).
15. Shu, S. et al. Response and resistance to BET bromodomain inhibitors in triplenegative breast cancer. Nature 529, 413-417 (2016).
16. Holohan, C., Van Schaeybroeck, S., Longley, D.B. & Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
17. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002).
18. Housman, G. et al. Drug resistance in cancer: An overview. Cancers (Basel) 6, 1769-1792 (2014).
19. Genschik, P., Sumara, I. & Lechner, E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J. 32, 2307-2320 (2013).
20. Vitari, A.C. et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474, 403-406 (2011).
21. Jang, M.K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523-534 (2005).
22. Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535-545 (2005).
23. Wu, S.Y., Lee, A.Y., Lai, H.T., Zhang, H. & Chiang, C.M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49, 843-857 (2013).
24. Zhuang, M. et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 36, 39-50 (2009).
25. Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
26. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015).
27. Theurillat, J.P. et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 346, 85-89 (2014).
28. Gan, W. et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917-930 (2015).
29. Zhong, Q. et al. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Sci. Rep. 6, 24146 (2016).
30. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305-309 (2014).
31. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
32. Winter, G.E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
33. Kumar-Sinha, C., Tomlins, S.A. & Chinnaiyan, A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497-511 (2008).
34. Rubin, M.A., Maher, C.A. & Chinnaiyan, A.M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 29, 3659-3668 (2011).
35. Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187 (2014).
36. Wei, W. et al. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428, 194-198 (2004).
37. Boehm, J.S., Hession, M.T., Bulmer, S.E. & Hahn, W.C. Transformation of human and murine fibroblasts without viral oncoproteins. Mol. Cell. Biol. 25, 6464-6474 (2005).
38. Inuzuka, H. et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCFâ-TRCP ubiquitin ligase. Cancer Cell 18, 147-159 (2010).
39. Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347-358 (2016).
40. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
41. Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M. & Reuter, V.E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur. Urol. 70, 106-119 (2016).